


388450.0002

PATENT

1647
#12/Jan
02.06.03

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Wayne P. Franco	37 C.F.R. § 1.8 Certificate of Mailing I hereby certify that this correspondence is today being deposited with the U.S. Postal Service in an envelope with appropriate postage affixed thereto and addressed to Commissioner for Patents and Trademarks, Washington, D.C. 20231. January 21, 2003.  Daniel F. Coughlin
Serial No.:	09/828,330	
Filing Date:	April 6, 2001	
Group Art Unit	1647	
Examiner	Christine J. Saoud	
Title of Application:	Methods of Use of Fibroblast Growth Factor, Vascular Endothelial Growth Factor and Related Proteins in the Treatment of Acute and Chronic Heart Disease	

RECEIVED

JAN 30 2003

TECH CENTER 1600/2900

January 21, 2003

Commissioner for Patents
Washington, DC 20231

TRANSMITTAL OF SEQUENCE LISTING

In response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures which accompanied the Office Action dated September 18, 2002, Transmitted herewith is a copy of the "Sequence Listing" in paper form for the above-identified patent application as required by 37 C.F.R. § 1.821(c). A copy of the Notice is also enclosed.

Two copies of the "Sequence Listing" in computer readable form as required by 37 C.F.R. § 1.821(e) and paper copy of the "Sequence Listing" are being mailed on even date herewith to United States Patent and Trademark Office, Box Sequence, P. O. Box 2327, Arlington, VA 22202.

As required by 37 C.F.R. § 1.821(f), Applicant's Attorney hereby states that the content of the "Sequence Listing" in paper form and the computer readable form of the "Sequence Listing" are the same.

Respectfully Submitted,



Daniel F. Coughlin, Reg. No. 36.111
Cummings & Lockwood
P. O. Box 1960
New Haven, CT 06509-1960
Tele: (203) 351-4622